A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Notes Sheet | |||||||||||||||||||||||||
2 | General: | |||||||||||||||||||||||||
3 | CEA created June 2017 (original here). Moral weights only updated February 2021. This spreadsheet was published in July 2023 to highlight calculation error | |||||||||||||||||||||||||
4 | Enter values in the "Parameters" and "Values Assignment" tabs. After filling in all your input values, view the "Results" section of the "Core calculations" tab. | |||||||||||||||||||||||||
5 | Resizing the formula bar in Google Sheets may make it easier to read the contents of explanatory cells | |||||||||||||||||||||||||
6 | ||||||||||||||||||||||||||
7 | ||||||||||||||||||||||||||
8 | Color code on "Parameters" and "Values" tabs: | |||||||||||||||||||||||||
9 | Orange indicates parameters that are both uncertain and likely to have major affects on results | |||||||||||||||||||||||||
10 | Pink marks parameters that are more certain or less influential | |||||||||||||||||||||||||
11 | Blue marks calculations | |||||||||||||||||||||||||
12 | ||||||||||||||||||||||||||
13 | Notes on model | |||||||||||||||||||||||||
14 | Types of benefits not included | |||||||||||||||||||||||||
15 | This CEA does not include any direct benefits from increases in Zinc coverage. Our understanding is that zinc is primarily expected to reduce morbidity from diarrhea whereas ORS accounts for the vast majority of impact on mortality. We do not factor in morbidity from diarrhea in our CEA, which is similar to GiveWell's approach to valuating the benefits of malaria cases averted. | |||||||||||||||||||||||||
16 | This CEA does not include any value of the program potentially averting deaths of persons over 5. We are highly uncertain about the program's effect on over-5 mortality. In contrast, GiveWell's CEA of AMF includes an estimate of over-5 deaths averted. | |||||||||||||||||||||||||
17 | This CEA does not include any value of the program potentially causing developmental benefits in children, due to decreased childhood illness, and potentially leading to better adult outcomes (such as higher incomes). GiveWell's CEAs of deworming and malaria control include such benefits. We are not aware of any literature examining the potential of reduced childhood diarrheal illness to lead to long-term increases in income. | |||||||||||||||||||||||||
18 | ||||||||||||||||||||||||||
19 | Types of costs not included | |||||||||||||||||||||||||
20 | This CEA does not include any negative or offsetting impacts of ORS/zinc treatment; we have not yet investigated such impacts | |||||||||||||||||||||||||
21 | This CEA does not currently account for the fact that some of the increase in ORS coverage may have come from people switching away from using recommended home fluids, which may have a smaller mortality impact than switching from other treatments | |||||||||||||||||||||||||
22 | This CEA has not yet carefully quantified government costs that may have supported the program. | |||||||||||||||||||||||||
23 | ||||||||||||||||||||||||||
24 | Under-5 deaths averted | |||||||||||||||||||||||||
25 | We have counted all diarrhea deaths averted as under-5 deaths averted. This is consistent with our current approach in AMF's CEA. | |||||||||||||||||||||||||
26 | ||||||||||||||||||||||||||
27 | ||||||||||||||||||||||||||
28 | ||||||||||||||||||||||||||
29 | Helpful GiveWell references: | |||||||||||||||||||||||||
30 | Top Charities | |||||||||||||||||||||||||
31 | Other cost-effectiveness analyses (including past years' versions) | |||||||||||||||||||||||||
32 | Discussion of cost-effectiveness as a criteria | |||||||||||||||||||||||||
33 | Blog posts discussing cost-effectiveness | |||||||||||||||||||||||||
34 | Cost-Effectiveness Analysis FAQ | |||||||||||||||||||||||||
35 | Cost-Effectiveness Analysis Video Walkthrough — Make sure to watch the video in HD in full screen to see details | |||||||||||||||||||||||||
36 | ||||||||||||||||||||||||||
37 | ||||||||||||||||||||||||||
38 | ||||||||||||||||||||||||||
39 | ||||||||||||||||||||||||||
40 |